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Abstract An increasing number of parents turn to
homeopathy for treatment of their hyperactive child.
Two publications, a randomised, partially blinded trial
and a clinical observation study, conclude that home-
opathy has positive eﬀects in patients with attention
deﬁcit hyperactivity disorder (ADHD). The aim of this
study was to obtain scientiﬁc evidence of the eﬀective-
ness of homeopathy in ADHD. A total of 83 children
aged 6–16 years, with ADHD diagnosed using the
Diagnostic and Statistical Manual of Mental Disorders-
IV criteria, were recruited. Prior to the randomised,
double blind, placebo controlled crossover study, they
were treated with individually prescribed homeopathic
medications. 62 patients, who achieved an improvement
of 50% in the Conners’ Global Index (CGI), partici-
pated in the trial. Thirteen patients did not fulﬁll this
eligibility criterion (CGI). The responders were split into
two groups and received either verum for 6 weeks fol-
lowed by placebo for 6 weeks (arm A), or vice-versa
(arm B). At the beginning of the trial and after each
crossover period, parents reported the CGI and patients
underwent neuropsychological testing. The CGI rating
was evaluated again at the end of each crossover period
and twice in long-term follow-up. At entry to the
crossover trial, cognitive performance such as visual
global perception , impulsivity and divided attention,
had improved signiﬁcantly under open label treatment
(P<0.0001). During the crossover trial, CGI parent–
ratings were signiﬁcantly lower under verum (average
1.67 points) than under placebo (P=0.0479). Long-term
CGI improvement reached 12 points (63%, P<0.0001).
Conclusion: The trial suggests scientiﬁc evidence of the
eﬀectiveness of homeopathy in the treatment of atten-
tion deﬁcit hyperactivity disorder, particularly in the
areas of behavioural and cognitive functions.
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behaviour Æ TAP: test battery for attention performance Æ
VLMT: German version of the Rey auditory verbal
learning test (RAVLT) Æ WISC-III: German version of
Wechsler intelligence scale for children
Introduction
The attention deﬁcit hyperactivity disorder (ADHD/
ADD) is a combination of disturbed attention (visual,
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tactile, auditory and proprioceptive) and hyperactivity/
impulsivity or passivity. Diagnostic criteria for the
disorder are six or more symptoms of either inatten-
tion, hyperactivity/impulsivity, or both [2]. ADHD is
one of the most common disorders of childhood,
occurring in 3%–5% of children, with male to female
ratios ranging from 3:1 to 9:1 [16]. Common medical
treatments are stimulants which fall under the legis-
lation for narcotics. Parents who do not want such
medication for their child increasingly seek homeo-
pathic alternatives [5,10]. Homeopathy is claimed to
inﬂuence disease using the eﬀect of highly diluted
substances, chosen according to the characteristic
individual symptoms of the patient. The aim of the
homeopathic physician is to ﬁnd the speciﬁc remedy
that corresponds accurately to the individual symp-
toms of the patient [11]. Since this process depends on
precise observations by patients or parents, the initial
phase of treatment is often characterised by the use of
diﬀerent medications until an optimal response is
reached. The eﬀectiveness of homeopathy, in which
the active substance is no longer traceable due to its
high dilution, is controversial.
Positive eﬀects of homeopathy on ADHD symp-
toms have been observed in a randomised, partially
blinded, placebo controlled crossover trial with 43
children by Lamont [17] who found signiﬁcant treat-
ment eﬀects. In an observation study with open label
treatment, Frei and Thurneysen [8] observed in 86 of
115 children an improvement of 55% in the Conners’
Global Index (CGI) rated by parents. Of the patients
in this study, 22% needed methylphenidate and 3%
reacted neither to homeopathy nor methylphenidate
[8]. A criticism of these trials is that, as they were not
completely blinded, there is no scientiﬁc evidence that
the improvements observed were the result of a
treatment eﬀect. Two large meta analyses have, how-
ever, concluded that the clinical eﬀects of homeopathic
treatments should not just be interpreted as a placebo
eﬀect [15,20]. The unsatisfactory methodology of many
of the studies analysed have, however, been criticised.
The suggestion that better trials in speciﬁc clinical
diseases are necessary to establish scientiﬁc evidence
for the eﬀectiveness of homeopathy led to the present
study.
Objectives
The primary objective was to investigate whether
homeopathy is signiﬁcantly distinct from placebo in the
treatment of ADHD. Neuropsychological tests best
suited to detect diﬀerences in children’s performance
during the trial were explored. Secondary objectives
were to deﬁne the time needed for satisfactory amelio-
ration of symptoms (i.e. to reach eligibility for the
crossover trial) and to assess the eﬀectiveness of long-
term treatment.
Methods
Design
The need for individually prescribed homeopathic
medication complicates the planning of a double blind
clinical trial, as blinding is only possible after the correct
individual medication for each patient has been found.
Since this process is particularly diﬃcult in ADHD pa-
tients, a straightforward randomised controlled trial was
considered impossible. In our previous study [8], we
made the observation that in early phase of ADHD
treatment with Q-potencies (Liquid homeopathic medi-
cations produced by dilution steps of 1:50,000, admin-
istered daily [22]), the improvement attained declines
within 4 weeks after stopping the medication and reap-
pears if treatment is restarted. The deterioration seen
when early treatment is interrupted could therefore be
used to test the diﬀerence between placebo and verum in
a crossover trial and led to the present study design. In
the ﬁrst phase of this study, children received individu-
ally prescribed homeopathic treatment (screening
phase). Children who achieved a pre-deﬁned level of
improvement then participated in a randomised, double
blind, placebo controlled crossover trial, to study dete-
rioration under placebo.
The double blind part of the study consisted of two
parallel groups of children who received verum (V) for 6
weeks followed by placebo (P) for 6 weeks (arm A: VP),
or placebo for 6 weeks followed by verum for 6 weeks
(arm B: PV). Both arms received another 6 weeks of
open label treatment (arm A: VPV, arm B: PVV) and an
additional long-term follow-up under treatment. The
length of each crossover period was determined using
the data from the previous study [8] and a preliminary
study in four children which revealed that the carry-over
eﬀect was longer than 4 weeks after stopping treatment.
Since a carry-over eﬀect may be an obstacle for a
crossover trial, relatively long crossover periods of 6
weeks were chosen. From previous experience, this
duration was thus considered long enough to diminish
this problem. No wash-out time was therefore incorpo-
rated between the two crossover periods.
Eligibility
Eligibility criteria for screening phase: age between 6 and
16 years, both genders, conﬁrmed ADHD according to
criteria of the Diagnostic and Statistical Manual of
Mental Disorders (DSM)-IV [2] and known neuropsy-
chological correlates (greater diﬃculty in learning,
memory, non-automated language tasks, and traditional
frontal executive measures) [6,23], necessity for treat-
ment, absence of any chronic physical, neurological or
psychiatric disorders. Necessity for treatment was as-
sumed if parents or teachers imperatively demanded an
intervention in order to improve the integration and
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performance of the patient in the family or school. A
primary selection of possible candidates was made using
the Conners’ Parent Rating Scale (CPRS), the Conners’
Teacher Rating Scale (CTRS) [7] and the Kinsbourne
Attention Questionnaire [14]. Patients complying with
the ADHD criteria in these questionnaires underwent
neuropsychological and neurological testing at the
Division of Paediatric Neurology of the University
Children’s Hospital Berne to conﬁrm the ADHD diag-
nosis. Subjects taking methylphenidate were obliged to
stop medication before neuropsychological testing.
Candidates not conforming to rigorous ADHD criteria
in the questionnaires were excluded. Patients were re-
cruited between January 2002 and September 2003 by
referral of informed paediatricians and by information
of regional ADHD parent organisations. All parents
previously knew about their participation in a study
involving homeopathy.
Assessment for conﬁrmation of diagnosis
A 2- to 4 h neuropsychological examination was per-
formed on patients by a paediatric psychologist and a
paediatric neurologist between January 2002 and Sep-
tember 2003. The tests were always arranged in the same
order. The organisation of the session and the time of day
for testing were identical for all subjects in order to avoid
eﬀects of uncontrolled factors on performance. The
investigation included the following tests: Checklist
DSM-IV criteria [2], Kaufman Assessment Battery for
Children (K-ABC) [13] or German version of Wechsler
Intelligence Scale for Children (WISC-III) [27], Test bat-
tery for Attention Performance (TAP) [30], the Largo
motor function test [18] and general physical and neuro-
logical examination. Children conforming to all diag-
nostic ADHDcriteria, including a parent-ratedCGI [7] of
at least 14 points without any treatment, were referred to
the homeopathic paediatrician for individual treatment.
Eligibility criteria for crossover trial
Patients must reach an amelioration of 50% of the initial
CGI value or at least 9 points during the screening
phase. Written informed consent was obtained from the
parents of each child.
Treatment and assessments
Screening phase: Patients entered homeopathic treat-
ment within 1 month after conﬁrmation of diagnosis.
Every eligible child was seen only once at the beginning
of the screening phase by the homeopathic physician to
minimise any further psychological support inﬂuencing
ADHD symptoms. They received an individually
prescribed homeopathic treatment daily according to
the guidelines described by Hahnemann [11] and
Boenninghausen [3]. Any other ADHD treatment was
prohibited throughout the whole study period and had
to stop immediately or subsequently. Compliance to this
rule was checked by periodical inquiry during treatment
monitoring and neuropsychological assessments. Treat-
ment progress was clinically assessed with parents only,
at intervals of 4 weeks by the homeopathic paediatrician
including regular reporting of the CGI. No other
counselling took place during these sessions. Adjustment
of the medication was made as necessary. The duration
of the screening phase was unlimited.
Crossover trial: Participants eligible for the crossover
trial were referred to the University Children’s Hospital
between September 2002 and February 2004 and as-
signed at random to treatment sequence arm A or B.
Patients, their parents, the investigators and the treating
physician were blind to the assigned treatments and the
treating physician had no contact with patients and
parents during the crossover trial. Children with acute
diseases, serious accidents and severe social changes in
their life during the crossover trial were not assessed for
all endpoints and were considered as dropouts; they
were, however, included in the primary endpoint anal-
ysis according to the intention-to-treat principle.
Open label treatment follow-up: At the end of the
second crossover period, all patients continued on open
label verum-treatment for an unlimited period of time.
Endpoints
The primary endpoint for the crossover trial was the
parents’ rating of CGI, a 10-item rating scale containing
the most important ADHD symptoms (i.e. temper
outbursts/excitable, impulsive/overactive/cries often/
inattentive/ﬁdgeting/disturbs other children/easily frus-
trated/fails to ﬁnish things/moods change quickly.
Rating: 0= never, 1= occasionally, 2= often, 3= very
often) [7]. Baseline value for the crossover trial was the
CGI assessed after the screening phase. The CGI and the
Questionnaire of Change of Behaviour (QCB) as well as
VLMT and subtests of WISC-III, K-ABC, Verbal
Learning Test (VLMT) [12] and TAP were evaluated at
the beginning of the crossover trial, after each crossover
period and 6 weeks after the crossover trial. To minimise
learning eﬀects, only a few of these tests were identical
with the diagnostic evaluation. The Connors’ question-
naire was completed again by parents and teachers 14
weeks after the crossover trial and a ﬁnal CGI was as-
sessed by the homeopathic paediatrician between April
2004 and September 2004 independent of the child’s
current state.
Ethics
The study was conducted in accordance with the Inter-
national Conference on Harmonisation, Guidelines for
Good Clinical Practice [19], the Declaration of Helsinki
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with all its amendments [29], and in compliance with
relevant regulations for informed consent and protection
of subject rights in Switzerland. The study protocol was
approved by the ethics committee of the Canton of
Berne and Swissmedic. The sponsors had no inﬂuence
on the design, implementation and publication of the
study.
Statistics
The sample size was calculated for the CGI, the primary
endpoint in the crossover trial. A mean reduction of
11.25 points (SD 4.00) in CGI had been observed in a
previous homeopathic study [8]. Four weeks after
interruption of treatment, the CGI increased by only 5
points (unpublished observation), indicating a possible
carry-over eﬀect of verum. If this eﬀect were strong,
measurements obtained during the second period should
be ignored [9]. A statistical test of carry-over eﬀect is,
however, not recommended [24]. To take into account
the potential carry-over eﬀect and drop-outs, the sample
size was therefore estimated using the conservative ap-
proach of a t -test for two parallel groups in the ﬁrst
period. A reduction of 5 points from pre-treatment value
due to verum was considered clinically relevant and a
zero point reduction was assumed under placebo. Tak-
ing into account the possibly greater heterogeneity in
this trial due to a diﬀerent recruitment practice when
compared with the previous study, the SD was inﬂated
to 5 for verum and the same value was assumed for
placebo. To have a 5% signiﬁcance level and a 95%
statistical power, 27 patients were required in each
treatment arm. Hence, a total of approximate 50–60
patients was planned. No interim analyses were con-
sidered.
Patient stratiﬁcation by age and CGI before treat-
ment start was used in the crossover trial: stratum 1: age
6–11 years, baseline CGI 14–21; stratum 2: age 6–11
years, baseline CGI 22–30; stratum 3: age 12–16 years,
baseline CGI 14–21; stratum 4: age 12–16 years, baseline
CGI 22–30. For each stratum, a randomisation list for
50 patients was computer-generated with a block size of
4 by the IMSV at the University of Berne. The random
treatment assignments were sealed in consecutively
numbered envelopes and given to the manufacturer
Spagyros, who produced the homeopathic medications
[11] and their placebos. Spagyros was informed in
writing by the treating physician when a child was eli-
gible for the double blind crossover study. The appro-
priate medication for that child was then prepared
according to the randomisation scheme. The medication
was sent by mail to the participating family at the
beginning of each crossover period. Placebos (20%
alcohol) were indistinguishable from verum in packag-
ing, labelling, colour and taste. There was no contact
between Spagyros, the investigators, the participants
and the treating physician during the crossover trial,
except when a child dropped out due to unexpected
problems.
Fig. 1 Participant ﬂow chart.
Left side: recruitment and
selection of participants for
screening phase. Participant
ﬂow during screening phase and
crossover trial. Right side:
dropouts at all levels
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The assessments of each outcome variable recorded
at the end of both crossover periods within a patient
were not independent. To analyse such correlated data, a
linear mixed model, including a random patient eﬀect, a
ﬁxed treatment eﬀect and a ﬁxed period eﬀect was ap-
plied using SAS version 8 [4,28]. With this approach,
patients who dropped out after the ﬁrst crossover period
could also be included in the analysis by assuming
missing at random. For other types of analyses, patients
with missing values were excluded. For selected vari-
ables of behaviour and cognitive performance, the
within-patient diﬀerences between diagnosis and
the beginning of the crossover trial were analysed using
the Wilcoxon signed rank test. The changes in CGI from
diagnosis to later time points were analysed by paired
t-test. All signiﬁcance tests were two-sided. All analyses
of secondary endpoints were of an exploratory nature
without adjustment for multiple testing. The statistician
was blinded to the sequence of the two study arms.
Results
Recruitment, participant ﬂow and baseline data
A total of 140 children were evaluated and 83 fulﬁlled
the rigorous criteria to enter the screening process. A
group of 70 children was eligible for and 62 participated
in the crossover study. Eight children dropped out due
to insuﬃcient response to homeopathy (three no re-
sponse at all, ﬁve partial responders with a median
improvement of 7 points, range 6–8) and ﬁve patients
dropped out due to compliance problems (median
improvement 6 points, range 3–8). All data presented
below were collected from the 62 children who partici-
pated in the crossover trial. Figure 1 shows details of the
recruitment phase and the participant ﬂow. Summaries
of the baseline data are presented in Table 1 and Ta-
ble 2. Patient characteristics were similar between
treatment arms (i.e. no statistically signiﬁcant diﬀerences
were found in baseline data between treatment arms
with one exception, number recall (K-ABC, P=0.0284).
The median CGI before treatment was 19 (range 15–
25) on both treatment arms. As usual in groups of
ADHD subjects, cognitive functions of the patients as
a group did not deviate much from the normal popu-
lation means (exception: auditory short term memory,
Table 2).
Screening phase
The 62 children participating in the crossover trial at-
tained the eligibility criteria after a mean treatment
duration of 5.1 months (SD 3.20, range 1–18 months)
with a median CGI of 8 (range 4–15). The following
homeopathic medications were used in potencies be-
tween Q 3 and Q 42 with success (number of patients):
Calcarea-carb. (15), Sulphur (8), Chamomilla (5),
Lycopodium (5), Silica (5), Hepar-sulph. (4), Nux-vom.
(4), China (3), Ignatia (3), Mercurius (3), Capsicum (1),
Causticum (1), Hyoscyamus (1), Phosphorus (1), Phos-
phoric-ac. (1), Sepia (1), Staphysagria (1) [1].
The neuropsychological tests assessed at diagnosis
and at entry to the crossover trial allow comparison of
performance throughout the screening phase. Highly
signiﬁcant improvement in visual detection of details,
impulsivity and divided attention were observed
(Table 3).
Crossover trial
Of the 62 randomised patients, 4 dropped out during the
crossover trial, three during crossover period one and
one during crossover period two (3 verum, 1 placebo).
Reasons for drop out were increasing tics, behavioural
problems and a reactive depression. Following the
intention-to-treat principle, all 62 patients were included
in the analysis.
Prior to the crossover trial, both treatment arms had
similar CGIs (8, range 3–16 in arm A vs. 9, range 4–20 in
Table 1 Baseline data, diagnostic criteria and CGI data. No statistically signiﬁcant diﬀerences were found in baseline data between
treatment arms
Arm A (n =31) Arm B (n =31)
Baseline data
Gender (girls/boys) 4/27 3/28
Median age (range) 10 (7–15) 10 (7–15)
Social situation (intact family/single parent) 23 (74%)/8 (26%) 20 (65%)/11 (35%)
Prior stimulant treatment 7 (23%) 4 (13%)
Clinical characteristics at diagnosis
DSM-IV criteria
Inattention ( n =56) 27 (87%) 29 (94%)
Hyperactivity/impulsivity ( n =36) 19 (61%) 17 (55%)
Inattention and hyperactivity/impulsivity ( n =31) 15 (48%) 16 (52%)
CGI data
Median before treatment, cut-oﬀ <14 (range) 19 (15–25) 19 (15–25)
Median at end of screening phase (range) 8 (5–14) 8 (4–15)
Ratio of changes with respect to before treatment value 58% 58%
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arm B, Fig. 2, point 1). Within-patient comparison of
treatment eﬀect shows that the CGI, the primary end-
point, decreased under verum with a mean of 1.67 points
(95% CI 3.316, -0.016) compared with placebo, indi-
cating a statistically signiﬁcant improvement in ADHD
symptoms with verum ( P =0.0479, Table 4). The per-
iod eﬀect was also statistically signiﬁcant, with a positive
parameter estimate of 2.19. The CGI was therefore on
average 2.19 points higher in crossover period one,
independent of treatment (12, range 3–24, verum in arm
A compared with 13, range 3–25, placebo in arm B,
Fig. 2, point 2). At the end of crossover period two,
ADHD symptoms decreased in children receiving verum
(CGI 9, range 3–19) while children on placebo still had a
high CGI (12, range 4–21) (Fig. 2, point 3). Also, at the
end of the following 6 weeks of open label treatment, the
ADHD symptoms of both treatment groups had re-
turned to around their values at beginning of the
crossover trial (8, range 2–16 in arm A vs. 8, range 2–21
in arm B Fig. 2, point 4).
Exploratory analysis of 70 neuropsychological
parameters during the crossover trial resulted in a few
within-patient diﬀerences in behavioural and cognitive
outcomes between placebo and verum, (Table 4): signif-
icantly better resistance to verbal interference in the
VLMT during the verum phase (P=0.0328) and a trend
towards amelioration of stability of mood and in reaction
to unexpected events were observed (P=0.0693 and
P=0.1001, respectively). Conversely, verum resulted in a
signiﬁcant reduction in alertness to visual details (picture
completion, WISC-III, P=0.0302) and a trend towards
decreasing performance in visual-spatial organisation
(bloc design, WISC-III, P=0.0632).
Open label treatment follow-up
Comparison of the scores CPRS scores between start of
treatment and 14 weeks after crossover trial still revealed
highly signiﬁcant improvements in all subscales, in both
Table 2 Baseline data from neuropsychological tests ( BC block counting, DA divided attention, GC gestalt closure, GN go/nogo, HM
hand movements, m mistakes, MA matrix analogies, NR number recall, PS photo series, STM short-term memory, TR triangles, WO
word order)
Arm A ( n =31) a Arm B ( n =31) a
Normal values Baseline values (mean ± SD)
Intelligence
General intelligence (K-ABC) 100±15 96.1±11.8 95.2±7.7
Sequential Processing Scale (K-ABC) 100±15 88.4±13.0 85.5±10.0
Simultaneous Processing Scale (K-ABC) 100±15 101.4±13.1 101.8±10.4
Memory
Sequential short-term memory (K-BC, HM) 10±3 8.5±3.2 8.7±2.5
Auditory abstract STM (K-ABC, NR) 10±3 7.6±2.0 6.3±1.8
Auditory semantic STM (K-ABC, WO) 10±3 8.3±2.9 8.1±2.5
Spatial short term memory (K-ABC, BC) 10±3 10.2±2.5 9.7±2.9
Perception
Visual global (K-ABC, GC) 10±3 10.0±2.6 10.5±2.1
Visual constructive (K-ABC, TR) 10±3 10.4±2.2 9.9±2.5
Executive functions
Inferential thinking (K-ABC, MA) 10±3 10.2±2.5 10.5±2.2
Performance sequences (K-ABC, PS) 10±3 10.1±2.4 10.4±2.5
Attention
Divided attention (TAP, DA, m) 50±10 48.4±11.7 45.2±12.4
Impulsivity (TAP, GN, m) 50±10 41.8±7.7 41.9±11.6
aNo statistically signiﬁcant diﬀerences were found in neuropsychological baseline data between treatment arms (exception attributable to
coincidental: number recall (K-ABC); P =0.0284)
Table 3 Results of screening phase. Total of observed diﬀerences in cognitive performance between diagnosis and crossover period one
(Wilcoxon signed rank test). ( C median of reaction time, GCA gestalt closure, SDB standard deviation of reaction time)
Outcome variable Median of diﬀerences Diﬀerence in % a P b Eﬀect
Visual global perception (GCA, K-ABC) -3 10.1 0.0001 Improvement
Impulsivity (Go/NoGo, SDB, TAP) -13 17.0 0.1044 Improvement
Impulsivity (Go/NoGo, median C, TAP) 17.5 16.2 0.0001 Improvement
Impulsivity (Go/NoGo, mistakes, TAP) -43 104.2 0.0001 Improvement
Divided attention (SDB, TAP) -30.5 24.1 0.0001 Improvement
Divided attention (median C, TAP) -32 44.3 0.0001 Improvement
Divided attention (missings, TAP) -29 24.6 0.0001 Improvement
Divided attention (mistakes, TAP) -30.5 27.1 0.0001 Improvement
aRatio of changes with respect to the before treatment values
bIf P <0.05, then the diﬀerence in performance between diagnosis and crossover period one is signiﬁcantly diﬀerent from zero
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mothers’ and fathers’ ratings. Teachers ratings (CTRS)
showed a signiﬁcant improvement in behaviour, and a
trend in improvement of the CGI. Impulsivity/hyper-
activity and passivity were improved, but did not reach
signiﬁcance in the teachers observations (Table 5). The
median CGI of the 62 children dropped signiﬁcantly
from 19 (range 15–25) at treatment start to 8 (range 2–
16) 6 weeks after the crossover trial (Fig. 3). At follow-
up 14 weeks after the crossover trial, however, a rise to
10 points (range 1–18) was observed (Fig. 3). This rise
may be attributable to lack of treatment compliance as
both children and parents were less likely to follow the
strict conditions of the crossover periods during con-
tinued open label treatment. At the ﬁnal assessment
(median duration of treatment 19 months, range 10–30
months: early entry into the trial led to longer follow-up
times), 53 children reached a median CGI of 7 points
(range 2–15) (Fig. 3), corresponding to an overall
improvement of 63% ( P <0.0001).
Discussion
The necessity of individual prescriptions in homeopathy
is a severe obstacle for any double blind trial. The
present study design, including a screening phase prior
the crossover trial, and analysing deterioration instead
of improvement during crossover trial, enabled us to use
individually prescribed medication in a double blind
trial. Since it is known that homeopathic medications
may produce strong carryover eﬀects and that these ef-
fects may compromise the results of a crossover trial,
placebo-phases had to be of a duration which was at the
limits of tolerance for a number of participating families.
Another limitation of the study design was the necessity
to exclude patients from the crossover trial who showed
an inadequate response to homeopathic treatment dur-
ing the screening phase. This means that the intention to
treat principle could not be followed through all the
way. The implications of this obstacle are discussed
Fig. 2 CGI course during
crossover trial according to
treatment arm (medians and
ranges). Arm A: unexpected rise
in CGI during verum phase,
possibly due to expectation of
receiving placebo in ﬁrst phase.
Persistent high CGI with
placebo in second phase,
normalisation of CGI with
open label verum after
crossover trial. Arm B: CGI
rose with placebo in ﬁrst phase
and returned to CGI values
within the normal range with
verum treatment in second
phase, as expected
Table 4 Results of crossover trial. Parameter estimates and P values of linear mixed models for outcome variables. ( BD bloc design, PC
picture completion)
Outcome variable Eﬀecta Parameter estimate P Eﬀect during verum period
CGI A (primary endpoint) Treatment -1.67 0.0479 Improvement
Period 2.19 0.0102
Verbal loss after interference B (VLMT) Treatment -11.27 0.0328 Improvement
Period -2.52 0.6294
Stability of mood C (QCB) Treatment 0.45 0.0693 Improvement
Period -1.07 <0.0001
Reaction to unexpected events D (QCB) Treatment 0.29 0.1001 Improvement
Period -0.67 0.0003
Alertness to visual details E (PC, WISC-III) Treatment -0.61 0.0302 Worsening
Period -0.92 0.0013
Visual spatial organisation F (BD, WISC-III) Treatment -0.63 0.0632 Worsening
Period 0.18 0.5843
aTreatment eﬀect refers to within-patient mean diﬀerence between treatments, i.e. verum-placebo. Period eﬀect refers to within-patient
mean diﬀerence between periods, i.e. period 1-period 2. Tests A and B measure intensity of symptoms, negative treatment eﬀect implies
improvement. Tests C, D, E and F measure capabilities, positive treatment eﬀect implies improvement
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below. Patients participating in the study were selected
by a rigorous diagnostic evaluation, ruling out any other
diagnosis but ADHD. In addition, strict inquiries at
periodical monitoring were performed to prevent the
application of any other treatment but homeopathy. The
long duration of observation of an average of 19 months
was chosen to grant that observed changes are not just
of transitory nature.
Eﬀects of homeopathy in children with ADHD have
been demonstrated in the present randomised double
blind crossover trial. The within-patient diﬀerence in
CGI between treatment with verum or placebo was
statistically signiﬁcant (P=0.0479) and supports the
positive eﬀect of homeopathy. However, CGI decreased
by only 17% (1.67 CGI points), somewhat less than that
expected from the results of an earlier study [8]. This
may be partially due to more precisely prescribed indi-
vidual homeopathic medication in this trial, with a
consequently stronger carry-over eﬀect. Another reason
for this small diﬀerence is the unexpected increase in
CGI during crossover period one in both treatment
groups. This increase could possibly be explained by a
psychological expectancy eﬀect [26]. Parents and chil-
dren both may have anticipated placebo in crossover
period one rather than two, and this presumed expec-
tancy (period) eﬀect was stronger than the treatment
Table 5 Long-term treatment eﬀects. Diﬀerences in CPRS and CTRS between diagnosis and follow-up 14 weeks after crossover trial
(Wilcoxon signed rank test)
CPRS Median of diﬀerences Diﬀerence in % P Eﬀect
Behaviour 3.5 42.5 0.0001 Improvement
Learning/attention 3 36.5 0.0001 Improvement
Psychosomatics 1 46.7 0.0004 Improvement
Impulsivity/hyperactivity 3 41.5 0.0001 Improvement
Shyness/anxiety 1 39.5 0.0001 Improvement
CGI 7 43.3 0.0001 Improvement
CTRS
Behaviour 3 36.4 0.0347 Improvement
Impulsivity/hyperactivity 2 28.0 0.1932 Improvement
Passivity 2 27.8 0.1184 Improvement
CGI 3 30.8 0.0561 Improvement
Fig. 3 Course of CGI between
diagnosis and follow-up
(median, quartile, range).
Alterations of CGI throughout
screening-phase, crossover trial
and long-term follow-up.
Transient rise after crossover
trial due to possible compliance
problems. The latest follow-up
during open label treatment
showed a maximum
amelioration of 12 points (63%)
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eﬀect. The question arises whether the parents just rated
the CGI in a way which they expected to be favourable
for the outcome of the study. While on treatment arm A
during the ﬁrst crossover period this might have actually
been the case, such a bias can be ruled out for crossover
period two on arm A, in which the same parents re-
ported a persistent deterioration under placebo. After
the initial (unexpected) worsening under verum, they
would report an improvement in crossover period two, if
their rating would follow just their opinion about what
should be a favourable outcome. However, in crossover
period two, the phenomenon disappeared and led to a
signiﬁcant decrease in the CGI of the verum group
(treatment eﬀect) whereas the placebo group maintained
an elevated CGI. The intended treatment eﬀect and the
unexpected period eﬀect together resulted in the ob-
served CGI levels, especially in crossover period one.
The treatment eﬀect became evident in crossover period
two. Following an additional 6 weeks of open label
treatment, both groups had CGI values similar to those
at the beginning of the crossover trial, an indirect con-
ﬁrmation of the appropriateness of the study design. The
validity of the CGI has been proven over time across
many studies and therefore won’t be doubted in the
context of this study [25].
Since at the beginning of the trial it was unknown
whether homeopathic treatment would aﬀect cognitive
functioning and which functions might possibly be af-
fected, a large number of cognitive variables, often im-
paired in ADHD children, were selected for study. The
trial design inevitably required a repetition of these tests
within a short period of time. Consequently, learning
eﬀects, which might mask possible treatment eﬀects,
were to be expected. Only a few signiﬁcant treatment
eﬀects were observed (positive: improved auditory short-
term memory, a trend to increased stability of mood,
better reactions to unexpected events; negative: decrease
in alertness to visual details and the trend towards de-
creased visual spatial organisation). These signiﬁcant
changes in neuropsychological tests during the crossover
trial may be due to chance only, as a result of the high
number of tests performed. The expected learning eﬀects
are indicated by signiﬁcant period eﬀects of many vari-
ables. A strong carry-over eﬀect with a persistence of
66% of the improvements reached under homeopathy
throughout the placebo phases, however, diminished the
possibility of positive neuropsychological tests further.
Eleven outliers in crossover period one and six in
crossover period two showed CGI-values contrary to the
expected courses, and diminished the statistical results
additionally in a way that the CGI diﬀerence between
placebo and verum was considerably smaller than ex-
pected.
Comparison of some of the cognitive tests at diag-
nosis and at the beginning of the crossover trial after the
initial open label homeopathic therapy suggests, how-
ever, highly signiﬁcant treatment eﬀects. Since every
other treatment was stopped during the screening phase,
this improvement is only explicable by the homeopathic
intervention. The question arises whether the eight pa-
tients who dropped out of the screening phase due to
insuﬃcient treatment response cause a selection bias
inﬂuencing the results considerably. Five of these
dropouts still had a partial amelioration under treat-
ment. Their inﬂuence on the high signiﬁcance of the
results of the screening phase and the long-term follow
up would therefore have been minimal. Thus, it is un-
likely that they would have caused considerably diﬀerent
results. Improvements in cognitive deﬁcits following
stimulant treatment of ADHD patients, especially spa-
tial working memory, attention-set shifting and visual
search performance have been reported [21]. The eﬀects
of homeopathy observed in this study are similar. To
gain a better insight into the quantitative aspects of
cognitive improvements following medication, a com-
parison of matched patients receiving stimulants,
homeopathy or placebo would be worthwhile.
The CGI and the CPRS scores (parent ratings) de-
creased between 37% and 63% over the long-term
observation period, most probably related to treatment
induced adjustment of behaviour. The CTRS improve-
ment ratings by teachers were smaller (between 28% and
37%) than those of the parents, reﬂecting the higher
cognitive stress for patients in school situations. How-
ever, on the whole, the overall intensity of ADHD
symptoms appears to be lower during treatment and
results in an improvement in the childrens’ social,
emotional and scholastic behaviour. The question whe-
ther these long-term improvements are a treatment eﬀect
or merely due to a spontaneous change in development
of the children cannot by deﬁnitely answered by our trial
data. However, the authors have observed that stopping
treatment after prolonged medication leads to a slow
decline of previous improvements over a time period of
several months in most children. Such a course cannot
just be explained by spontaneous evolution and is highly
suggestive of a treatment eﬀect.
The results of this trial point to the eﬀectiveness of
homeopathy in the treatment of ADHD. To corroborate
the ﬁndings presented here, the authors suggest a larger
and independent multicentre study. Since homeopathic
treatment of ADHD is not an easy undertaking, a
training phase for participating treating physicians in the
methodology used in this study would be essential prior
to starting the trial. Diﬀerent homeopathic approaches
might lead to other observations. Factors limiting the
widespread use of homeopathy in the treatment of
ADHD are the time needed for amelioration of symp-
toms, thus excluding this treatment from use in emer-
gency situations, and the necessity of accurate
observation and recording of symptoms by the parents.
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